Stocks · News reference
Pacific Biosciences Of California Approves Restructuring Plan To Align With Strategic Initiatives; Restructuring To Reduce Workforce By About 8%; Expects $30M-$40M Annualized Operating Expense Reduction By End Of 2027; Estimates $2M Pre-Tax Charges For Reduction In Force
On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuring plan to continue to better align the Company’s organizational structure and resources with its strategic
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo, PacBio and others posted double-digit gains.
PacBio, TychoBio Collaborate Over Generation Of RNA Data To Train Models For RNA Therapy Design
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR
The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.